کلرمادینون استات (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "کلرمادینون استات" in Persian language version.

refsWebsite

Global rank Persian rank

4^th place

5^th place

2^nd place

11^th place

52^nd place

3^rd place

6^th place

low place

books.google.com

Hughes A, Hasan SH, Oertel GW, Voss HE, Bahner F, Neumann F, et al. (27 November 2013). Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. pp. 490, 508, 516–517, 524, 531. ISBN 978-3-642-80859-3.
Mydlo JH, Godec CJ (11 July 2003). Prostate Cancer: Science and Clinical Practice. Academic Press. pp. 437–. ISBN 978-0-08-049789-1.

Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Bouchard P (2005). "Chlormadinone acetate (CMA) in oral contraception--a new opportunity". The European Journal of Contraception & Reproductive Health Care. 10 (Suppl 1): 7–11. doi:10.1080/13625180500434889. PMID 16356876. S2CID 22898956.
Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.
Ishizuka O, Nishizawa O, Hirao Y, Ohshima S (November 2002). "Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy". Int. J. Urol. 9 (11): 607–12. doi:10.1046/j.1442-2042.2002.00539.x. PMID 12534901. S2CID 8249363.

Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Bouchard P (2005). "Chlormadinone acetate (CMA) in oral contraception--a new opportunity". The European Journal of Contraception & Reproductive Health Care. 10 (Suppl 1): 7–11. doi:10.1080/13625180500434889. PMID 16356876. S2CID 22898956.
Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.
Kanimoto Y, Okada K (November 1991). "[Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results]". Hinyokika Kiyo (به ژاپنی). 37 (11): 1423–8. PMID 1722627.
Ishizuka O, Nishizawa O, Hirao Y, Ohshima S (November 2002). "Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy". Int. J. Urol. 9 (11): 607–12. doi:10.1046/j.1442-2042.2002.00539.x. PMID 12534901. S2CID 8249363.

Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Bouchard P (2005). "Chlormadinone acetate (CMA) in oral contraception--a new opportunity". The European Journal of Contraception & Reproductive Health Care. 10 (Suppl 1): 7–11. doi:10.1080/13625180500434889. PMID 16356876. S2CID 22898956.
Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.
Ishizuka O, Nishizawa O, Hirao Y, Ohshima S (November 2002). "Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy". Int. J. Urol. 9 (11): 607–12. doi:10.1046/j.1442-2042.2002.00539.x. PMID 12534901. S2CID 8249363.